OncoSec Medical Inc (ONCSQ)

[guti]

Thanks, it is appreciated! I found some reading which supports what many have not realized. Oncosec is aiming for first line therapy in Cancer.

Dr. Pierce knew when he decided to take on ImmunoPulse IL-12, that electrochemo-gene theory had already being proven. In 2003 a clinical study showed how intratumoral delivery of Interleukin-12 gene and bleomycin synergistically induced therapeutic immunity when performed by means of electroporation. Although either both bleomycin alone or IL-12, significantly suppressed the tumors, the combination therapy drastically improved the results. It significantly prolonged the mean survival period, while Natural killer and T lymphocyte activities were markedly enhanced in the mice that received the chemo-gene therapy. More important, the study concluded that electroporation delivery of IL-12 and a chemotherapy drug elicits innate and adaptive anti melanoma responses.

Bleomycin is a type of chemotherapy drug which is used as first line chemotherapy regimen when tumors are in their beginning stage. In everyday practice, doctors look for other options and caution is taken when using agents like anti PD-1 or any other combination. Radiation is the option for localized disease, since toxicity and the cost of these agents prevent their use as first line therapy. Multiple new approaches are promising, but the future is in the use of combination treatment with standard chemotherapy which soon can become replaced by ImunoPulse IL-12.